Duloxetine Hydrochloride + placebo

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Anxiety Disorders

Conditions

Anxiety Disorders

Trial Timeline

Jan 1, 2005 → Mar 1, 2007

NCT ID

NCT00122863

About Duloxetine Hydrochloride + placebo

Duloxetine Hydrochloride + placebo is a phase 3 stage product being developed by Eli Lilly for Anxiety Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT00122863. Target conditions include Anxiety Disorders.

What happened to similar drugs?

19 of 20 similar drugs in Anxiety Disorders were approved

Approved (19) Terminated (2) Active (1)

✅Duloxetine + PlaceboEli LillyApproved

✅Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatmentSumitomo PharmaApproved

✅Cariprazine + PlaceboAbbVieApproved

✅EscitalopramAbbVieApproved

✅QuetiapineAstraZenecaApproved

✅Quetiapine extended release tablet + PlaceboAstraZenecaApproved

✅QuetiapineAstraZenecaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00673452	Approved	Completed	Jun 1, 2008	Jul 1, 2009	Fibromyalgia
NCT00536471	Approved	Completed	Sep 1, 2007	Dec 1, 2008	Major Depressive Disorder
NCT00422162	Approved	Completed	Feb 1, 2007	Aug 1, 2008	Major Depressive Disorder
NCT00408993	Phase 3	Completed	Dec 1, 2006	Feb 1, 2008	Diabetic Neuropathies
NCT00406848	Approved	Completed	Nov 1, 2006	Nov 1, 2009	Major Depressive Disorder
NCT00244296	Approved	Completed	Oct 1, 2005	Jan 1, 2007	Urinary Incontinence, Stress
NCT00191919	Phase 3	Completed	May 1, 2005	May 1, 2006	Depressive Disorder, Major
NCT00122863	Phase 3	Completed	Jan 1, 2005	Mar 1, 2007	Anxiety Disorders
NCT00122824	Phase 3	Completed	Jun 1, 2004	Sep 1, 2005	Anxiety Disorders
NCT00190996	Phase 3	Completed	Jan 1, 2003	Jun 1, 2006	Urinary Incontinence, Stress
NCT00058968	Phase 3	Completed	Oct 1, 2002	Mar 1, 2005	Diabetic Neuropathy, Painful

Competing Products

20 competing products in Anxiety Disorders

See all competitors

Product	Company	Stage	Hype Score
Duloxetine + venlafaxine + placebo	Eli Lilly	Phase 3	40
ONO-1110 + Placebo	Ono Pharmaceutical	Phase 2	39
Duloxetine + Placebo	Eli Lilly	Phase 3	40
duloxetine hydrochloride + placebo	Eli Lilly	Phase 3	40
Duloxetine + Placebo	Eli Lilly	Approved	43
duloxetine + placebo	Eli Lilly	Phase 3	40
Duloxetine + venlafaxine + placebo	Eli Lilly	Phase 3	40
Duloxetine + Placebo	Eli Lilly	Phase 3	40
eszopiclone + eszopiclone + Placebo	Sumitomo Pharma	Phase 2	35
Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatment	Sumitomo Pharma	Approved	43
risperidone oral tablets	Johnson & Johnson	Phase 3	40
ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT)	AbbVie	Phase 2	42
Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/day	AbbVie	Phase 2	27
ABBV-932 + Placebo	AbbVie	Phase 1	29
Cariprazine + Placebo	AbbVie	Approved	43
Escitalopram	AbbVie	Approved	43
Quetiapine	AstraZeneca	Approved	43
Quetiapine extended release tablet + Placebo	AstraZeneca	Approved	43
AZD7325 + Radioligand (11C) flumazenil	AstraZeneca	Phase 1	29
AZD7325 + AZD7325 + AZD7325 + Placebo	AstraZeneca	Phase 2	35